JP7353281B2 - 大環状化合物およびそれらの使用 - Google Patents

大環状化合物およびそれらの使用 Download PDF

Info

Publication number
JP7353281B2
JP7353281B2 JP2020527111A JP2020527111A JP7353281B2 JP 7353281 B2 JP7353281 B2 JP 7353281B2 JP 2020527111 A JP2020527111 A JP 2020527111A JP 2020527111 A JP2020527111 A JP 2020527111A JP 7353281 B2 JP7353281 B2 JP 7353281B2
Authority
JP
Japan
Prior art keywords
cancer
compound
optionally substituted
pharmaceutically acceptable
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020527111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512046A (ja
JP2021512046A5 (https=
Inventor
キシ，ヨシト
和信 吉良
憲 伊藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Harvard University
Original Assignee
Eisai R&D Management Co Ltd
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd, Harvard University filed Critical Eisai R&D Management Co Ltd
Publication of JP2021512046A publication Critical patent/JP2021512046A/ja
Publication of JP2021512046A5 publication Critical patent/JP2021512046A5/ja
Priority to JP2023122183A priority Critical patent/JP2023156359A/ja
Application granted granted Critical
Publication of JP7353281B2 publication Critical patent/JP7353281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2020527111A 2017-11-15 2018-11-15 大環状化合物およびそれらの使用 Active JP7353281B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023122183A JP2023156359A (ja) 2017-11-15 2023-07-27 大環状化合物およびそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762586416P 2017-11-15 2017-11-15
US62/586,416 2017-11-15
US201862765310P 2018-08-20 2018-08-20
US62/765,310 2018-08-20
PCT/US2018/061250 WO2019099646A1 (en) 2017-11-15 2018-11-15 Macrocyclic compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023122183A Division JP2023156359A (ja) 2017-11-15 2023-07-27 大環状化合物およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2021512046A JP2021512046A (ja) 2021-05-13
JP2021512046A5 JP2021512046A5 (https=) 2021-12-23
JP7353281B2 true JP7353281B2 (ja) 2023-09-29

Family

ID=64664436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020527111A Active JP7353281B2 (ja) 2017-11-15 2018-11-15 大環状化合物およびそれらの使用
JP2023122183A Pending JP2023156359A (ja) 2017-11-15 2023-07-27 大環状化合物およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023122183A Pending JP2023156359A (ja) 2017-11-15 2023-07-27 大環状化合物およびそれらの使用

Country Status (6)

Country Link
US (3) US11407762B2 (https=)
EP (2) EP3710454B1 (https=)
JP (2) JP7353281B2 (https=)
CN (2) CN111566113B (https=)
ES (1) ES2974243T3 (https=)
WO (1) WO2019099646A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023156359A (ja) * 2017-11-15 2023-10-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状化合物およびそれらの使用
US12421248B2 (en) 2017-04-05 2025-09-23 President And Fellows Of Harvard College Macrocyclic compound and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
HUE061306T2 (hu) 2017-07-06 2023-06-28 Harvard College Halikondrinok szintézise
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016003975A1 (en) 2014-06-30 2016-01-07 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
JPS61191687A (ja) 1985-02-20 1986-08-26 Fujisawa Pharmaceut Co Ltd ハリコンドリンｂ
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
DE4229425A1 (de) 1992-09-03 1994-03-10 Kodak Ag Vorrichtung zum stapelweisen Ablegen und Ausrichten von einzeln zugeführten Blättern
US5426194A (en) 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US5352804A (en) 1993-01-19 1994-10-04 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 2
JP2818381B2 (ja) 1994-01-18 1998-10-30 帝人株式会社 ７−チアプロスタグランジン類およびその製造法
US5519050A (en) * 1995-04-07 1996-05-21 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of halistatin 3
US6214865B1 (en) 1998-06-17 2001-04-10 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
JP2001305734A (ja) 2000-04-20 2001-11-02 Fuji Photo Film Co Ltd 光重合性組成物
JP2003261447A (ja) 2002-03-07 2003-09-16 Kyosei Seiyaku Kk 抗腫瘍剤
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
EP1831697A4 (en) 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SEARCH FOR TUBULINISOTYPES IN CANCER THERAPY USING HALICHONDRIN B ANALOG
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
MY153742A (en) 2007-03-07 2015-03-13 Interdigital Tech Corp Method and apparatus for generating and processing a mac-ehs protocol data unit
US20100254996A1 (en) 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
RU2010118063A (ru) 2007-11-16 2011-12-27 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Новое промежуточное соединение для синтеза аналога галихондрина в и новая реакция десульфонилирования, применяемая для получения промежуточного соединения
CN105801599A (zh) 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
WO2011094339A1 (en) 2010-01-26 2011-08-04 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
WO2012096926A2 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
CN104024237B (zh) 2011-12-16 2016-02-24 阿方拉研究股份有限公司 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体
CN104080793B (zh) 2011-12-29 2017-09-19 阿方拉研究股份有限公司 2‑((2s,3s,4r,5r)‑5‑((s)‑3‑氨基‑2‑羟基丙‑1‑基)‑4‑甲氧基‑3‑(苯磺酰甲基)四氢呋喃‑2‑基)乙醛衍生物以及它们的制备方法
WO2013142999A1 (en) 2012-03-30 2013-10-03 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
AR096238A1 (es) 2013-05-15 2015-12-16 Alphora Res Inc Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
CA2916537C (en) 2013-07-03 2021-07-27 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
EP3689881B1 (en) 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
MX384292B (es) 2013-12-06 2025-03-14 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
WO2016038624A1 (en) 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
KR102743950B1 (ko) 2015-05-07 2024-12-18 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤라이드의 합성에 유용한 마크로고리화 반응 및 중간체 및 기타 단편
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
WO2018008667A1 (ja) 2016-07-07 2018-01-11 新日本理化株式会社 動力伝達用潤滑油基油
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
JP2020508315A (ja) 2017-02-20 2020-03-19 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ がんを治療するための薬剤組合せ
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
ES2931533T3 (es) * 2017-04-05 2022-12-30 Harvard College Compuesto macrocíclico y usos del mismo
JP2019013861A (ja) 2017-07-03 2019-01-31 住友化学株式会社 ガス分離膜エレメント、ガス分離膜モジュール、及びガス分離装置
HUE061306T2 (hu) 2017-07-06 2023-06-28 Harvard College Halikondrinok szintézise
WO2019009956A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College SUMMARY OF MEDIUM MEDIATED KETONE
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20230135188A1 (en) 2017-07-06 2023-05-04 President And Fellows Of Harvard College Fe/cu-mediated ketone synthesis
CN111566113B (zh) * 2017-11-15 2024-01-09 哈佛大学的校长及成员们 大环化合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016003975A1 (en) 2014-06-30 2016-01-07 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Angew. Chem. Int. Ed.，2017年，56，10796-10800
Bioorg. Med. Chem.，2009年，17，2199-2203
Tetrahedron Letters，1992年，Vol.33, No.12，1557-1560

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12421248B2 (en) 2017-04-05 2025-09-23 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
JP2023156359A (ja) * 2017-11-15 2023-10-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状化合物およびそれらの使用

Also Published As

Publication number Publication date
US20200325152A1 (en) 2020-10-15
ES2974243T3 (es) 2024-06-26
EP3710454B1 (en) 2024-01-03
EP3710454A1 (en) 2020-09-23
JP2023156359A (ja) 2023-10-24
CN111566113A (zh) 2020-08-21
WO2019099646A1 (en) 2019-05-23
US20240309014A1 (en) 2024-09-19
US11407762B2 (en) 2022-08-09
WO2019099646A8 (en) 2020-01-23
US11814398B2 (en) 2023-11-14
EP4403560A2 (en) 2024-07-24
CN117924310A (zh) 2024-04-26
EP4403560A3 (en) 2024-10-23
US20230016686A1 (en) 2023-01-19
CN111566113B (zh) 2024-01-09
JP2021512046A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
US12528767B2 (en) HDAC6 inhibitors and uses thereof
JP7353281B2 (ja) 大環状化合物およびそれらの使用
US11155562B2 (en) Synthesis of halichondrin analogs and uses thereof
EP2550285B1 (en) Trioxacarcins and uses thereof
EP3505521A1 (en) Cortistatin analogues and syntheses and uses thereof
WO2018085247A1 (en) Compounds for malt1 degradation
JP6408478B2 (ja) トリオキサカルシン、トリオキサカルシン−抗体複合体、およびその用途
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
WO2018165385A1 (en) Inhibitors of malt1 and uses thereof
WO2022169985A1 (en) Hdac6 inhibitors and uses thereof
WO2024220676A1 (en) Mrna degraders and methods of use thereof
WO2024097948A1 (en) Degraders of mdm2 and uses thereof
US20250144227A1 (en) C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof
WO2019032961A1 (en) TRIOXACARCIN-ANTIBODY CONJUGATES AND USES THEREOF
WO2023150203A1 (en) Hdac6 inhibitors and uses thereof
WO2021142115A1 (en) Sanglifehrin analogs and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230728

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230919

R150 Certificate of patent or registration of utility model

Ref document number: 7353281

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150